乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ESC

<乌鸦传媒>ESC: Ticagrelor Fails to Improve on Clopidogrel After Switch

Single-center study contradicts PLATO in ACS patients

<乌鸦传媒>ESC: Huge Diet Study Shows Carbs, Not Fats Are the Problem

But PURE also challenges belief that more is better for fruits and vegetables

<乌鸦传媒>ESC: Merck REVEALS a Slightly Positive CETP Inhibitor Trial

A CETP inhibitor scores after 3 strikes for the class

<乌鸦传媒>ESC: Concomitant LAA Closure During Heart Surgery Scores a Win

But will making it routine safely prevent strokes?

<乌鸦传媒>ESC: A Second Opinion on NOACs in Stable CVD

Raymond Gibbons, MD, takes apart the COMPASS trial in favor of optimal medical therapy

<乌鸦传媒>ESC: No BP Spike Seen with Celecoxib Use

But ibuprofen boosts systolic pressure

<乌鸦传媒>ESC: Supplemental Oxygen Doesn't Save Lives in Suspected MI

Despite no harm in trial, 'it is clearly time for clinical practice to change'

<乌鸦传媒>ESC: Is Low BMI a Bigger Problem than Obesity After PCI?

Reverse J-curve seen for hospital stay, readmission, costs

<乌鸦传媒>ESC: NOAC Combo Tx Can Eliminate Need for Aspirin After PCI

Fewer bleeds and similar ischemic protection seen in RE-DUAL trial

<乌鸦传媒>Guns at Doors, But ESC Carries On

Barcelona meeting attracts 31,000

<乌鸦传媒>Inflammation, Secondary Prevention, Diet in Spotlight at ESC

CANTOS, COMPASS, PURE will headline the world's largest cardiology meeting

<乌鸦传媒>We Have Ruined Late-Breaking Clinical Trials in Cardiology

In this Revolution and Revelation, Milton Packer explains why a cornerstone of annual meetings has gone from sizzler to snoozer

<乌鸦传媒>Barcelona Attack Doesn't Derail ESC Plans

Cardiologists hang tough: 'If we change behavior, the terrorists have won'

<乌鸦传媒>CANTOS to Headline ESC

August's European Society of Cardiology meeting lineup released

<乌鸦传媒>ESC: Pope Backs Medical Research in Historic Speech

Addresses cardiology meeting in Rome

<乌鸦传媒>ESC: Medical Therapy Adequate for Plaque Erosion

Pilot study suggests stenting not needed in uncomplicated cases

<乌鸦传媒>ESC: Savaysa Safe for Afib Cardioversion

ENSURE-AF trial finds similarity to standard anticoagulant regimen

<乌鸦传媒>ESC: Winners Emerge in CAD Imaging Showdowns

Promising results for cardiac MRI, MPS, and PET

<乌鸦传媒>ESC: PCSK9 Tx -- Ready for Prime Time or Still Unproven?

Debate highlights pros and cons of these cholesterol-lowering drugs

<乌鸦传媒>ESC: NOAC Reversal Agent Effective in Study

But results may not sway FDA

<乌鸦传媒>ESC: DES or BMS? No Mortality Difference

After 6 years, death was as likely in DES patients as in BMS patients

<乌鸦传媒>ESC: Beta-Blocker Cuts Early Heart Damage from Cancer Tx?

No clinical difference in small trial, but preclinical measures suggestive

<乌鸦传媒>CardioBrief: Cardiologists Give SPRINT Thumbs Down

Trial should not be used in guidelines to lower blood pressure targets

<乌鸦传媒>ESC: Platelet Testing Still Doesn't Work in 2016

No clinical benefits observed even the elderly

<乌鸦传媒>ESC: CPAP Flops for Secondary CV Prevention

No impact on coronary, stroke risks from sleep apnea tx in SAVE trial

<乌鸦传媒>ESC: No Mortality Benefit With ICD in Nonischemic HF

Eleven fewer deaths over 5 years

<乌鸦传媒>ESC: Will CvLPRIT Change Practice?

BARCELONA -- Cardiologists react to findings from the CvLPRIT study, which challenge not only traditional thinking but also existing guidelines from both the U.S. and Europe, all of which say that treating nonculprit arteries in STEMI patients may be harmful.

<乌鸦传媒>ESC: Mixed Results with Steroids in TB Pericarditis

BARCELONA -- Adding steroids to anti-tuberculosis treatment for patients with tuberculous pericarditis can reduce the risk of complication and the resulting hospital admission, but adding prednisolone to tuberculosis treatment did not reduce the risk of death, researchers said here.

<乌鸦传媒>ESC: Xarelto Safe for Cardioverting Afib

BARCELONA -- Switching atrial fibrillation patients awaiting elective cardioversion to rivaroxaban (Xarelto) was as safe as warfarin in that setting.

<乌鸦传媒>ESC: Peto Analysis Called Short on Proof of Simvastatin/ Ezetimibe Cancer Safety

SEATTLE -- Simvastatin/ezetimibe (Vytorin) may increase the risk of cancer after all, concluded a leading American biostatistician who dismissed as prematurely reassuring an analysis by Richard Peto, Ph.D., F.R.S., that found the link with excess malignancy to be overblown.

<乌鸦传媒>ESC: In CABG versus Stent Trial, the Edge Goes to Bypass

MUNICH -- The latest round in the surgeons versus interventional cardiologists appears to have gone to the surgeons. So it would seem from today's roundtable discussion at the European Society of Cardiology meeting here.